Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Dietary dicarboxylic acids provide a nonstorable alternative fat source that protects mice against obesity
Eric S. Goetzman, … , Steven F. Dobrowolski, Birgit Schilling
Eric S. Goetzman, … , Steven F. Dobrowolski, Birgit Schilling
Published April 30, 2024
Citation Information: J Clin Invest. 2024;134(12):e174186. https://doi.org/10.1172/JCI174186.
View: Text | PDF
Research Article Metabolism Article has an altmetric score of 1

Dietary dicarboxylic acids provide a nonstorable alternative fat source that protects mice against obesity

  • Text
  • PDF
Abstract

Dicarboxylic fatty acids are generated in the liver and kidney in a minor pathway called fatty acid ω-oxidation. The effects of consuming dicarboxylic fatty acids as an alternative source of dietary fat have not been explored. Here, we fed dodecanedioic acid, a 12-carbon dicarboxylic (DC12), to mice at 20% of daily caloric intake for 9 weeks. DC12 increased metabolic rate, reduced body fat, reduced liver fat, and improved glucose tolerance. We observed DC12-specific breakdown products in liver, kidney, muscle, heart, and brain, indicating that oral DC12 escaped first-pass liver metabolism and was utilized by many tissues. In tissues expressing the “a” isoform of acyl-CoA oxidase-1 (ACOX1), a key peroxisomal fatty acid oxidation enzyme, DC12 was chain shortened to the TCA cycle intermediate succinyl-CoA. In tissues with low peroxisomal fatty acid oxidation capacity, DC12 was oxidized by mitochondria. In vitro, DC12 was catabolized even by adipose tissue and was not stored intracellularly. We conclude that DC12 and other dicarboxylic acids may be useful for combatting obesity and for treating metabolic disorders.

Authors

Eric S. Goetzman, Bob B. Zhang, Yuxun Zhang, Sivakama S. Bharathi, Joanna Bons, Jacob Rose, Samah Shah, Keaton J. Solo, Alexandra V. Schmidt, Adam C. Richert, Steven J. Mullett, Stacy L. Gelhaus, Krithika S. Rao, Sruti S. Shiva, Katherine E. Pfister, Anne Silva Barbosa, Sunder Sims-Lucas, Steven F. Dobrowolski, Birgit Schilling

×

Figure 4

DC12 is metabolized using both peroxisomes and mitochondria.

Options: View larger image (or click on image) Download as PowerPoint
DC12 is metabolized using both peroxisomes and mitochondria.
(A and B) M...
(A and B) Male 129S1 mice (n = 5) were adapted to HFD or an isocaloric DC12 diet for 5 weeks. Serum was collected early during the night cycle, and tissues late in the night cycle, and they were used for mass spectrometry to detect DCAs. (C and D) Proteomics results from tissues collected after 5 weeks on the diets (n = 3), expressed as log2 of the fold-change of DC12-treated animals over HFD. Also see proteomics data in Supplemental Tables 1–6. Gold dots represent proteins that were significantly increased and blue dots are proteins that were significantly decreased (absolute log2FC > 0.58, q < 0.05), while gray are proteins with no significant change. Black lines indicate the mean of each condition. (E) Heatmap showing the absolute levels of key peroxisomal FAO proteins across the 5 different tissues. Heatmap values are means of n = 3; ND, not detected. Asterisks indicate statistically significant pairwise differences (q < 0.01), either upregulated by DC12 diet (red font) or downregulated (green font). (F–H), 14C-labeled DC12 or palmitate (C16) were used to probe the rates of total FAO (no etomoxir) or peroxisomal FAO (etomoxir-resistant) in whole cells. All bar graphs represent means and SDs. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as determined with 2-sided Student’s t test. Liv, liver; Kid, kidney; Mus, muscle; Brn, brain; and Hrt, heart. Panel E created with BioRender.com.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
15 readers on Mendeley
See more details